pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,013 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT785Endpoints590BioPharma Dive228onclive165BioSpace63Fierce Biotech63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
    AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
    STAT · 1mo ago↗ source
  • STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes
    The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.
    STAT · 1mo ago↗ source
  • STAT+: Novo underwhelmed by drug it once fought Pfizer for
    Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
    STAT · 1mo ago↗ source
← prev
page 19 of 41
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
    Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
    STAT · 1mo ago↗ source
  • STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
    Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
    STAT · 1mo ago↗ source
  • Major readouts from the annual diabetes conference
    Why "Schedule F" matters, the Ebola outbreak response, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
    A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.
    STAT · 1mo ago↗ source
  • When it’s time to save a limb, novel clinic meets unhoused people where they are
    Unmet vascular needs can lead to limb loss among unhoused patients. An unusual Massachusetts General Hospital program meets patients where they are.
    STAT · 1mo ago↗ source
  • Opinion: American horses are obese, too
    “American horses are getting sick in ways that look remarkably familiar,” writes Joshua Moen.
    STAT · 1mo ago↗ source
  • Opinion: $2 million gene therapy cures require a financing model
    “We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.
    STAT · 1mo ago↗ source
  • STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
    STAT · 1mo ago↗ source
  • STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
    Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
    STAT · 1mo ago↗ source
  • STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
    STAT · 1mo ago↗ source
  • STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
    Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
    STAT · 1mo ago↗ source
  • STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
    Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
    STAT · 1mo ago↗ source
  • Opinion: How the Amish think about vaccines, health care costs, and much more
    There may be nearly 2 million Amish Americans by 2075. That has large public health implications.
    STAT · 1mo ago↗ source
  • Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
    “Ebola is an unforgiving enemy,” writes Tom Frieden, who led the U.S. CDC response to the 2014-2016 Ebola outbreak.
    STAT · 1mo ago↗ source
  • CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures
    The Ebola outbreak in Central Africa could grow to 20,000 cases or more, depending on how quickly infected people are isolated to slow the spread, according to a new U.S. analysis.
    STAT · 1mo ago↗ source
  • STAT+: Newer GLP-1s, pushback on research cuts, and a protest
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
    STAT · 1mo ago↗ source
  • STAT+: What stripping civil service protections for thousands of federal workers will mean for HHS
    Thousands of HHS staff who shape policy have had their employment status changed to a designation that makes it easier for them to be fired.
    STAT · 1mo ago↗ source
  • Senior NIH official pushes MAHA strategy to skeptical ADA audience
    An NIH advisor told researchers gathered at the American Diabetes Association conference that MAHA goals match the agency's priorities.
    STAT · 1mo ago↗ source
  • Opinion: If Americans risk their lives fighting Ebola overseas, they deserve the right to come home
    Outbreak response is difficult enough without asking responders to wonder whether they will have access to the best available care if they become ill.
    STAT · 1mo ago↗ source
  • STAT+: Will Makary’s FDA voucher program survive?
    RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news
    STAT · 1mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 1mo ago↗ source
  • Texas AG investigating energy drinks
    The limitations of private health insurance, the quiet collapse of America's research ethics watchdog and other Morning Rounds news
    STAT · 1mo ago↗ source